Baidu
map

Stroke:颅内闭塞的轻度缺血性卒中患者的影像学特征

2021-11-14 MedSci原创 MedSci原创

三分之一的轻度卒中患者会发生早期神经功能恶化,主要是由于相关颅内闭塞。近日,心血管疾病领域权威杂志Stroke上发表了一篇研究文章,研究人员分析了这些患者的血管闭塞模式、血栓特征和再通率。

三分之一的轻度卒中患者会发生早期神经功能恶化,主要是由于相关颅内闭塞。近日,血管疾病领域权威杂志Stroke上发表了一篇研究文章,研究人员分析了这些患者的血管闭塞模式、血栓特征和再通率。

在INTERRSeCT研究招募的患者中,这是一项在颅内闭塞的急性缺血性卒中患者中进行的多中心前瞻性研究,研究人员比较了轻(美国国立卫生研究院卒中量表评分≤5)至中度/重度卒中。

在575名患者中,12.9%的患者美国国立卫生研究院卒中量表评分≤5(中位年龄为70.5[63-79];58%为男性;美国国立卫生研究院卒中量表评分中位数为4[2-4])。两组的人口统计学和血管危险因素相似。与美国国立卫生研究院卒中量表评分>5的患者相比,轻度患者从症状发作至评估时间(开始至计算机断层扫描[240 vs. 167分钟]和计算机断层扫描血管造影[246 vs. 172分钟])时间更长,闭塞部位更远(M3,大脑前动脉和大脑后动脉;22% vs. 6%),凝块负荷评分更高(中位数为9[6-9] vs. 6[4-9]),相似的有利血栓通透性(残余血流等级I-II,21% vs. 19%),更高的侧支血流量(9.1 vs. 7.6)和较低的静脉阿替普酶治疗率(55% vs. 85%)。

与中度/重度卒中(26%;相比于阿替普酶组29%)相比,轻度患者更可能再通(修订的动脉闭塞量表评分2b/3为45%;阿替普酶组为49%)。在性别、阿替普酶、残余流量和两次血管成像之间的时间的调整模型中,静脉使用阿替普酶(比值比为3.80[95%CI为1.11-13.00])和残余流量等级(比值比为8.70[95%CI为1.26-60.13])与轻度患者成功再通有关。

由此可见,与中度/重度卒中相比,颅内闭塞的轻度卒中具有不同的血管闭塞模式但相似的血栓通透性。较高的血栓通透性和阿替普酶的使用与成功的再通有关,尽管大多数患者不会再通。需要随机对照试验来评估新的溶栓剂和血管内治疗在该人群中的疗效。

原始出处:

H. Lee Lau.et al.Radiographic Characteristics of Mild Ischemic Stroke Patients With Visible Intracranial Occlusion: The INTERRSeCT Study.stroke.2021.https://www.ahajournals.org/doi/10.1161/STROKEAHA.120.030380

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1893444, encodeId=73cb189344462, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Dec 20 13:55:25 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720429, encodeId=74471e2042980, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Mar 05 08:55:25 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806474, encodeId=b4cb18064e48a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon May 23 17:55:25 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010442, encodeId=ba6f2010442ba, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sun Mar 27 03:55:25 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072002, encodeId=178810e200213, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/560f15a0277d43b6a97093df9d0bd9c6/495b8d7c43964f24a256a019fb92ab8e.jpg, createdBy=4aac5114077, createdName=1461fe16m02, createdTime=Sat Nov 20 08:42:48 CST 2021, time=2021-11-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1893444, encodeId=73cb189344462, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Dec 20 13:55:25 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720429, encodeId=74471e2042980, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Mar 05 08:55:25 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806474, encodeId=b4cb18064e48a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon May 23 17:55:25 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010442, encodeId=ba6f2010442ba, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sun Mar 27 03:55:25 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072002, encodeId=178810e200213, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/560f15a0277d43b6a97093df9d0bd9c6/495b8d7c43964f24a256a019fb92ab8e.jpg, createdBy=4aac5114077, createdName=1461fe16m02, createdTime=Sat Nov 20 08:42:48 CST 2021, time=2021-11-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1893444, encodeId=73cb189344462, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Dec 20 13:55:25 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720429, encodeId=74471e2042980, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Mar 05 08:55:25 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806474, encodeId=b4cb18064e48a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon May 23 17:55:25 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010442, encodeId=ba6f2010442ba, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sun Mar 27 03:55:25 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072002, encodeId=178810e200213, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/560f15a0277d43b6a97093df9d0bd9c6/495b8d7c43964f24a256a019fb92ab8e.jpg, createdBy=4aac5114077, createdName=1461fe16m02, createdTime=Sat Nov 20 08:42:48 CST 2021, time=2021-11-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1893444, encodeId=73cb189344462, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Dec 20 13:55:25 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720429, encodeId=74471e2042980, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Mar 05 08:55:25 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806474, encodeId=b4cb18064e48a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon May 23 17:55:25 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010442, encodeId=ba6f2010442ba, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sun Mar 27 03:55:25 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072002, encodeId=178810e200213, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/560f15a0277d43b6a97093df9d0bd9c6/495b8d7c43964f24a256a019fb92ab8e.jpg, createdBy=4aac5114077, createdName=1461fe16m02, createdTime=Sat Nov 20 08:42:48 CST 2021, time=2021-11-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1893444, encodeId=73cb189344462, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Dec 20 13:55:25 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720429, encodeId=74471e2042980, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Mar 05 08:55:25 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806474, encodeId=b4cb18064e48a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon May 23 17:55:25 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010442, encodeId=ba6f2010442ba, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sun Mar 27 03:55:25 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072002, encodeId=178810e200213, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/560f15a0277d43b6a97093df9d0bd9c6/495b8d7c43964f24a256a019fb92ab8e.jpg, createdBy=4aac5114077, createdName=1461fe16m02, createdTime=Sat Nov 20 08:42:48 CST 2021, time=2021-11-20, status=1, ipAttribution=)]
    2021-11-20 1461fe16m02

    受益匪浅

    0

相关资讯

JNNP:急性功能性假性卒中与轻度急性缺血性卒中的长期随访比较

每年都有许多患者因怀疑患有急性缺血性中风(AIS)而入住急诊室。有几种情况可以表现为急性中风样症状,其中最常见的是癫痫发作、偏头痛和功能紊乱。后者被称为假性功能性中风(FSM)。虽然AIS患者的预后已

Neurology:模拟实测下,神经病学研究生处理急性缺血性卒中能否令人满意?

模拟实测下, 神经学研究生在急性缺血性中风的初始治疗中表现令人放心,但在溶栓后出血转化的治疗中经常出错,这表明需要围绕这一低频率、高敏锐度的事件进行更多的教育。

Stroke:低血压、合并症与缺血性卒中死亡率的关系

与正常血压相比,卒中前较低的血压与卒中后死亡率相关,尤其是在至少有一种合并症的患者中。

Stroke:COVID-19住院患者缺血性卒中的风险、临床过程和结局

COVID-19住院患者急性缺血性卒中的累积发生率约为2%,在重症监护病房接受治疗的患者风险更高。大多数卒中患者的预后不佳。缺血性卒中与肺栓塞之间的关联值得进一步研究。

Stroke : 卒中患者,出院后,他们康复如何?

该研究的重要意义提供了一套基于专家共识的关键因素,在确定脑卒中患者出院后护理的地点时需要考虑

Stroke:阿司匹林治疗失败的缺血性卒中患者抗血栓治疗可预防卒中

在接受阿司匹林预防性治疗的缺血性卒中患者中,近一半患者出院时使用阿司匹林单药治疗,而没有改变抗血栓药物类别,而另一半出院时使用氯吡格雷单药治疗、双联抗血小板治疗或其他不太常见的药物治疗。

Baidu
map
Baidu
map
Baidu
map